Gregory Fraser
Stock Analyst at Truist Securities
(4.42)
# 365
Out of 4,415 analysts
31
Total ratings
61.54%
Success rate
16.78%
Average return
Main Sectors:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $1.22 | +555.74% | 6 | Apr 30, 2024 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $72 → $80 | $67.25 | +18.96% | 6 | Mar 1, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $6.01 | +49.75% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $6.76 | +3.55% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $24.52 | +18.27% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $14.78 | +542.76% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $13.30 | +35.34% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $8.60 | +365.12% | 2 | May 26, 2023 | |
| BHC Bausch Health Companies | Downgrades: Hold | n/a | $7.82 | - | 1 | Jul 29, 2022 |
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.22
Upside: +555.74%
ANI Pharmaceuticals
Mar 1, 2024
Maintains: Buy
Price Target: $72 → $80
Current: $67.25
Upside: +18.96%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $6.01
Upside: +49.75%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $6.76
Upside: +3.55%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $24.52
Upside: +18.27%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $14.78
Upside: +542.76%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $13.30
Upside: +35.34%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $8.60
Upside: +365.12%
Bausch Health Companies
Jul 29, 2022
Downgrades: Hold
Price Target: n/a
Current: $7.82
Upside: -